Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are currently used as second-line therapy for treatment of patients with type 2 diabetes mellitus (T2DM). Based on the results from dedicated cardiovascular outcome trials (CVOTs), current guidelines suggest the use of SGLT-2 inhibitors for patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Avgerinos, Ioannis, Liakos, Aris, Tsapas, Apostolos, Bekiari, Eleni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899064/
https://www.ncbi.nlm.nih.gov/pubmed/31819580
http://dx.doi.org/10.2147/DMSO.S190356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899064/
https://www.ncbi.nlm.nih.gov/pubmed/31819580
http://dx.doi.org/10.2147/DMSO.S190356

Ejemplares similares